__NUXT_JSONP__("/drugs/Telisotuzumab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1781223-80-0",chebiId:b,chemicalFormula:b,definition:"An immunoglobulin G1 (IgG1) humanized monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Telisotuzumab binds to c-Met, thereby preventing both c-Met binding to its ligand, HGF and the subsequent activation of the HGF\u002Fc-Met signaling pathway. This may cause cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.",fdaUniiCode:"R15ZW356HN",identifier:"C106262",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C164001"],synonyms:["ABT-700","Anti-c-Met Monoclonal Antibody ABT-700","TELISOTUZUMAB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FTelisotuzumab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Telisotuzumab","","2021-10-30T13:17:56.143Z")));